Project Grant R01MH134889
Award Date
9/5/24
Completion Date
7/31/29
Dollars Obligated
$666K
Federal Agency
National Institute of Mental Health
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to develop a decision support tool for early introduction of clozapine treatment in first-episode psychosis (FEP) patients. The $779,842 award, effective September 5, 2024 through July 31, 2029, will fund a multi-center, randomized clinical trial to evaluate the efficacy of using biomarkers (functional brain scan, genetic tests for weight gain and...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $795,000 to the University of California, San Diego (UCSD) to conduct a multi-center, randomized clinical trial. The goal is to develop a Clozapine decision support tool using biomarkers to improve outcomes for first-episode psychosis (FEP) patients who are at risk of poor response to conventional first-line antipsychotics. The study will...
The National Institute of Mental Health (NIMH) awarded a $731,452 Project Grant under CFDA 93.242 (Mental Health Research Grants) to the University of Alabama at Birmingham (UAB) to conduct a multi-center, randomized clinical trial. The goal is to develop a decision support tool using biomarkers to guide the use of the antipsychotic medication clozapine for first-episode psychosis (FEP) patients who are at risk of poor response to first-line antipsychotics. The key biomarkers being evaluated...
The National Institute of Mental Health (NIMH) awarded a Project Grant under the Mental Health Research Grants program (CFDA 93.242) to The Feinstein Institutes for Medical Research, a non-profit medical research organization, for $1,217,886 on September 5, 2024. The goal of this 5-year project is to develop a clozapine decision support tool for first-episode psychosis (FEP) patients based on three specific biomarkers: a functional brain scan, a genetics test for weight gain risk, and a genetics...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to validate a predictive biomarker in the cerebellar-cortical circuitry for assessing treatment response to antipsychotic medication in patients with first-episode psychosis. The $519,558 award, granted on June 15, 2025, will support a 5-year research project conducted by The Feinstein Institutes for Medical Research. The key objectives are to: 1)...
This Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 Mental Health Research Grants provides $508,500.00 to New York University to leverage electronic health records, dimensional phenotyping, and genetic analysis to build predictive models and identify subtypes of clinical outcomes among individuals with schizophrenia. The project aims to advance precision psychiatry by developing individualized treatment planning, outcome monitoring, and preventive...
This Project Grant award from the National Institute of Mental Health (CFDA 93.242 - Mental Health Research Grants) provides $2,048,026 to The Trustees of Columbia University in the City of New York to conduct research on using machine learning approaches and integrated electronic health records, dimensional phenotyping, and genetic analyses to build predictors and identify subtypes of clinical outcomes among individuals with schizophrenia. The project aims to advance precision psychiatry by...
This Project Grant award of $535,153 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund a large-scale, single-cell characterization of molecular and cellular networks involved in mood regulation in major depressive disorder (MDD). The project aims to identify transcriptomic changes associated with MDD in a sample of 800 subjects across three key brain regions: the anterior cingulate cortex, basolateral amygdala, and...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), seeks to harness collective intelligence to predict outcomes for individuals at clinical high-risk for psychosis. The $334,588 award to Beth Israel Deaconess Medical Center, Inc. (Bidmc) will fund a 2-year project to evaluate the predictive accuracy of psychiatrists and a multidisciplinary group, using clinical data and risk calculator...
This $784,642 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program will support research at the New York Genome Center, Inc. (Nygc) to leverage electronic health records, dimensional phenotyping, and genomic analysis to develop predictive models for clinical outcomes in psychosis-related disorders. The key objectives are to: 1) Build machine learning models to forecast treatment response, illness severity, medical...